InvestorsObserver
×
News Home

Is Crinetics Pharmaceuticals Inc (CRNX) a Winner in the Biotechnology Industry?

Friday, November 10, 2023 12:25 PM | InvestorsObserver Analysts

Mentioned in this article

Is Crinetics Pharmaceuticals Inc (CRNX) a Winner in the Biotechnology Industry?

The 84 rating InvestorsObserver gives to Crinetics Pharmaceuticals Inc (CRNX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 97 percent of stocks in the Biotechnology industry, CRNX’s 84 overall rating means the stock scores better than 84 percent of all stocks.

Overall Score - 84
CRNX has an Overall Score of 84. Find out what this means to you and get the rest of the rankings on CRNX!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 84 would rank higher than 84 percent of all stocks.
Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Crinetics Pharmaceuticals Inc Stock Today?

Crinetics Pharmaceuticals Inc (CRNX) stock has fallen -0.71% while the S&P 500 has risen 0.8% as of 12:24 PM on Friday, Nov 10. CRNX is lower by -$0.19 from the previous closing price of $26.69 on volume of 165,855 shares. Over the past year the S&P 500 is higher by 10.76% while CRNX has risen 42.55%. CRNX lost -$3.64 per share the over the last 12 months. Click Here to get the full Stock Report for Crinetics Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App